Navigation Links
Herbal remedy used to treat hepatitis C proves ineffective, Penn study finds
Date:7/19/2012

PHILADELPHIA - Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania. Milk thistle fruit extracts have been widely used by patients in treating liver disease based on previous evidence showing that it has anti-inflammatory, anti-oxidant, and potentially anti-viral properties. However, the new study is the first rigorous trial of its kind conducted to assess true efficacy in a group of hepatitis C patients who were previously unsuccessfully treated with interferon-based therapy the standard anti-viral method used to treat the disease. Full results of the study are published in the July 18 issue of The Journal of the American Medical Association.

The Centers for Disease Control and Prevention (CDC) estimates that 3.2 million persons in the United States have chronic hepatitis C virus (HCV) infection. Of those, the study says 33 percent have reported current or past use of silymarin to treat the disease. The new study was designed to measure the potential benefit of increasing doses of silymarin in patients with chronic HCV. To determine efficacy, researchers monitored levels of serum alaninie aminotransferase (ALT) the enzyme found in the blood stream that is most often tested to identify liver disease. Low levels of ALT are normally found in the blood, but are elevated when the liver is damaged or diseased. Secondary outcomes included quality-of-life measures.

"By all indications, silymarin is no more effective at treating hepatitis C related chronic liver disease, in those who failed standard therapy with interferon, than a placebo," said K. Rajender Reddy, MD, professor of Medicine and medical director of Liver Transplantation at Penn Medicine, and senior author of the study. "This is a landmark study as millions of people around the world are looking for supplements and other forms of alternative medicines to help reduce ALT levels every year."

The trial, which included 154 adult participants with chronic HCV, was conducted over the course of two years at four medical centers in the United States. Participants were randomly assigned to receive 420mg silymarin, 700mg silymarin or a matching placebo administered three times/week for 24 weeks, a standard duration of treatment. After 24 weeks, researchers found only two participants in each treatment group achieved lowered ALT levels. Neither the average decline in ALT activity nor quality-of-life measures at the end of treatment differed significantly across the treatment groups.

"These data show that even higher-than-normal doses of silymarin don't significantly reduce ALT levels for patients with HCV," said Reddy, noting that the doses used in the trial were three and five times higher than the customary dose. "At the end of the trial we saw no significant changes in physical or mental health assessments between the patients who received treatment, and those who did not. Quality-of-life measures were also largely unchanged."


'/>"/>

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-349-5964
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Herbal Remedy Ingredient Tied to Cancer, Kidney Failure
2. Efficacy of herbal remedies for managing insomnia
3. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
4. Clinical insight improves treatment with new lung cancer drug
5. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
6. Study Suggests Treating Dyslexia Before Kids Learn to Read
7. Rapid Asthma Treatment in ER May Prevent Admission
8. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
9. Breast cancer patients suffer treatment-related side effects long after completing care
10. Mayo Clinic offers newly approved treatment for acid reflux disease
11. Mobile Stroke Units Might Trim Time to Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology: